GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bioray Biotech Co 7561.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

16.30

+1.88%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Bioray Biotech Co

Its shares trade on Taipei Exchange under the ticker 7561.TWO. It has been listed since 6 July 2020. In the fiscal year to 31 December 2025, it reported revenue of TWD 222.7m and net income of TWD 32.3m. At that date it held total assets of TWD 536.6m and shareholders' equity of TWD 453.0m.

BioRay Biotech Co., Ltd. engages in the biological health products development, functional Medical Testing business, and cell storage and preparation services. The company is headquartered in Tainan, Tainan. The company went IPO on 2020-07-06. The firm also provides functional medical testing services, as well as cell storage and preparations business. The health products include personalized probiotics, anti-allergic and intestinal probiotics, diabetes probiotics, female urinary tract, anti-arthritis probiotics, among others. The testing services include personalized bacteria, personalized fungi, intestinal normal bacteria, quantitative detection of magnesium in red blood cells, polymorphism analysis of metabolic related genes, lymphocyte grouping. The cell storage and preparations include stem cell storage, immune cell storage, cytokine induced killer (CIK) immune cell preparations, among others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
6 Jul 2020

Leadership

Pay as last reported

  • Mr. Ting-Yuan HsuChairman of the Board, since 2024
  • Ms. Chun-Mei LuGeneral Manager, since 2019
  • Mingting WangDirector
  • Mr. Chengyun XieDirector
  • Mr. Fuxiang LiIndependent Director
  • Mr. Minshou YanIndependent Director
  • Yuming YangIndependent Director
  • Jyun-Hong JhouIR Contact Officer

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Offers personalized probiotics and functional medical testing services
  • Provides cell storage and preparation services including stem cell storage
  • Headquartered in Tainan with an IPO in 2020

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • Limited details on financial performance or market position
  • No mention of competitive advantages or unique technologies

Opportunities

  • Expansion of personalized health products market
  • Growing demand for functional medical testing services
  • Potential growth in cell storage and preparation services

Threats

  • Competition in the biotechnology sector
  • Regulatory challenges in health and medical services
  • Dependence on market trends for health products

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.